Sign In
Last checked at 
19 Mar 2020 07:00
19 March 2020
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Director Dealing
Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Christian Hoyer Millar (Chief Executive Officer) has purchased 4,000 Ordinary Shares of 1 pence each at an average price of 66.5 pence per share.
Following this transaction, Christian Hoyer Millar, together with his wife, is interested in 12,358,303 Ordinary Shares, representing approximately 13.35% of the Company's current issued share capital.
The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
a) | Name | Christian Hoyer Millar | ||||||
2 | Reason for the notification | |||||||
a) | Position/status | Director/PDMR | ||||||
b) | Initial notification/ Amendment | Initial notification | ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | Oxford BioDynamics Plc | ||||||
b) | LEI | 2138005Y1TK258O5U928 | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each
ISIN: GB00BD5H8572 | ||||||
b) | Nature of the transaction | Acquisition of ordinary shares | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information - Aggregated volume - Price
|
| ||||||
e) | Date of the transaction | 16 March 2020
| ||||||
f) | Place of the transaction | Outside a trading venue | ||||||
For further details please contact:
Oxford BioDynamics Plc Christian Hoyer Millar, CEO Paul Stockdale, CFO
| +44 (0)1865 518910 |
Shore Capital Nominated Adviser and Broker Stephane Auton Edward Mansfield | +44 (0)20 7408 4090 |
FTI Consulting Financial Public Relations Adviser Natalie Garland-Collins | +44 (0)20 3727 1000 |
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.
Follow the stocks
